Day: May 28, 2024

NOT FOR DISSEMINATION TO U.S. WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES The prospectus supplement, the corresponding base shelf prospectus and any amendment thereto in connection with this offering will be accessible through SEDAR+ within two business days CALGARY, Alberta, May 28, 2024 (GLOBE NEWSWIRE) — Tidewater Midstream and Infrastructure Ltd. (“Tidewater” or the “Company”) (TSX: TWM) announced today a public offering (the “Offering”), on a “bought deal” basis, of $75 million principal amount of convertible unsecured subordinated debentures (the “Debentures”), at a price of $1,000 per Debenture, with an interest rate of 8.00% per annum, payable semi-annually on the last day of June and December, commencing on December 31, 2024. The Debentures will mature on June 30, 2029. The Debentures will be convertible at the...

HAMILTON, Bermuda, May 28, 2024 (GLOBE NEWSWIRE) — SiriusPoint Ltd. (“SiriusPoint” or the “Company”) (NYSE:SPNT), a global specialty insurer and reinsurer, has today announced the appointment of Susan Cross as Board Director, effective May 24, 2024. Susan takes up a new role on the SiriusPoint Board, bringing the total number of members to 10. Susan has over 40 years of experience in the (re)insurance industry, with a focus on developing and leading actuarial and analytical functions to support global growth. She has been a Director of Enstar Group Limited (Enstar) since October 2020, and prior to that served as Executive Vice President and Global Chief Actuary at XL Group (now AXA XL), from 2008 to 2018. In addition to the SiriusPoint and Enstar Boards, Susan serves as Non-Executive Director at Unum Group, a Fortune 500 insurer....

Quarterly supplemental dividends of $0.075 per share represent a 20% increase in dividend payments to common shareholders Increased dividend payments reflect material outperformance of containership charter markets ATHENS, Greece, May 28, 2024 (GLOBE NEWSWIRE) — Global Ship Lease, Inc. (NYSE:GSL) (the “Company”), a containership charter owner, today announced the introduction of a quarterly supplemental dividend to common shareholders. Recent containership charter market strength is enabling Global Ship Lease to secure higher-than-anticipated cashflows from time charters with longer-than-anticipated durations. As a result, in addition to the sustainable dividend of $0.375 per Class A common share per quarter, commencing with the dividend payable after the release of the Company’s earnings for the second quarter of 2024, Global...

~ Full Year 2024 Adjusted Net Income Guidance Increased to $122 Million to $128 Million ~ LA JOLLA, Calif., May 28, 2024 (GLOBE NEWSWIRE) — Palomar Holdings, Inc. (NASDAQ: PLMR) (“Palomar” or the “Company”) today announced the successful completion of certain reinsurance programs incepting June 1, 2024, and increased the Company’s full year 2024 adjusted net income guidance. The Company procured approximately $400 million of incremental limit to support the growth of its Earthquake franchise. Palomar’s reinsurance coverage now extends to $3.06 billion for earthquake events, $735 million for Hawaii hurricane events, and $117.5 million for all continental United States hurricane events. The reinsurance program provides ample capacity for the Company’s growth in the subject business lines as well as coverage to a level exceeding Palomar’s...

New name and NYSE trading symbol (“ONIT”) expected to be effective June 10, 2024PHH Mortgage expected to rebrand to Onity Mortgage in the fall of 2024 WEST PALM BEACH, Fla., May 28, 2024 (GLOBE NEWSWIRE) — Ocwen Financial Corporation (NYSE: OCN) (“Ocwen” or the “Company”), a leading non-bank mortgage servicer and originator, today announced that the Company has obtained the necessary approval from its shareholders to change the name of Ocwen to Onity™ Group Inc. Glen A. Messina, Chair, President and CEO of Ocwen, said, “We are very pleased that our shareholders have approved our name change to Onity Group. We look forward to this new chapter in our Company’s history and to operating under the Onity brand, which reflects the evolution of our culture and the transformation of our Company. Rebranding to Onity signifies the...

New data from the completed dose escalation part and ongoing expansion part of Study 1100, an ongoing US Phase 1 study evaluating NBTXR3 followed by anti-PD-1 in patients with recurrent or metastatic head and neck cancer (n=68) to be presented by Coordinating Investigator Colette Shen, MD, PhD, at ASCO 2024 Following the ASCO presentation, Nanobiotix will host an investor event on Sunday, June 2nd at 12:00 PM EDT / 6:00 PM CEST to review the presented resultsPARIS and CAMBRIDGE, Mass., May 28, 2024 (GLOBE NEWSWIRE) — NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced the presentation of updated data from the completed...

Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million; Exploring strategic options to maximize shareholder value BOSTON, May 28, 2024 (GLOBE NEWSWIRE) — Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”) today announced discontinuation of the clinical IK-930 program, the Company’s TEAD1- selective Hippo pathway inhibitor and continued clinical development of IK-595, a novel MEK-RAF molecular glue. Concurrently, Ikena is evaluating strategic options for both the Company and its development pipeline. “Ikena is dedicated to thoughtfully putting our capital to work towards impactful treatments for patients, and in doing so building value for our shareholders. Together with our board of directors,...

ROUYN-NORANDA, Canada, May 28, 2024 (GLOBE NEWSWIRE) — Abcourt Mines Inc. (“Abcourt” or the “Company”) (TSX Venture : ABI) is pleased to announce that it has just obtained from the Ministry of Natural Resources and Forests of Quebec, the necessary authorizations to undertake stripping and drilling work (Impact Work Authorization, ATI) for its Flordin and Discovery properties in the Lebel-sur-Quévillon area. Abcourt will shortly undertake field work on these properties with the aim of determining, based on the results obtained, future locations which will be subject to monitoring by stripping and drilling. The first phase of work which will begin in June will be concentrated between the Flordin deposit and Cartwrigth with the aim of validating the possible connection between the two mineralized zones. Note that the sector is sub-outcropping...

BOSTON, May 28, 2024 (GLOBE NEWSWIRE) — Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that its Board of Directors has appointed Thomas Schuetz, M.D., Ph.D., President of Research and Development and Vice Chair of the Board of Directors of the Company, as President and Chief Executive Officer of the Company, effective May 28, 2024. Vered Bisker-Leib, Ph.D., M.B.A., has stepped down as Chief Executive Officer and as a member of the Board of Directors of the Company, effective May 28, 2024. Dr. Bisker-Leib will continue to be available to the Company as a Senior Consultant for the next 15 months. “I am very enthusiastic to return to my prior role as CEO at Compass. I continue...